IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization

Nov 5, 11:30 AM·

High Optimistic

Sources

globenewswire.com /

Summarized by i88

Tickers

Summary

Late-breaking ELSPIRE data presented at The Liver Meeting 2026 and published in HEPATOLOGY show 85.3% of IQIRVO-treated patients achieved ALP normalization at Week 52 in primary biliary cholangitis, versus 23% in the comparator arm. The results support broader positioning for IQIRVO in PBC; no ticker was specified in the release.

Late-breaking results from the ELSPIRE study show that 85.3% of patients receiving IQIRVO achieved normalization of ALP at Week 52, compared with 23% in the comparator arm, according to the source release.

Presentation and publication

The ELSPIRE results will be presented as late-breaking data at The Liver Meeting 2026 and simultaneously published in HEPATOLOGY, described in the release as AASLD’s flagship journal.

Key data point

At Week 52, 85.3% of patients receiving IQIRVO achieved normalization of ALP.
The comparator arm recorded 23%.

Context

The release frames the data as raising ambitions in PBC (primary biliary cholangitis). No ticker was specified in the release.

AI in Ophthalmology Market Size, Share, and Trends Analysis 2026-2036: Evaluates AI Adoption Across Ophthalmic Imaging, Diagnostics, Surgical Planning, and Clinical Workflows

Brunswick annonce une augmentation de la taille de son placement sous le régime de la dispense pour financement de l’émetteur coté et son placement privé simultané annoncés précédemment pour un produit brut pouvant atteindre 20 million $

Repligen: 3 Key Takeaways for Long-Term Investors